According to the results of a new clinical trial, stem cell transplants are likely to induce remission of multiple sclerosis in the long run. The trial indicates that high-dose immunosuppressive therapy and transplantation of an individual’s own stem cells may stimulate sustained reduction of relapsing-remitting multiple sclerosis. After five years of receiving high-dose immunosupprresive therapy treatment and autologous hematopoietic cell transplant, 69 percent of the participants did not experience continued disability. Additionally, they did not suffer from progression of MS symptoms or a relapse. Noteworthy, after obtaining HDIT/HCT, participants did not take any medication. Some studies have noted that the success rates of the present MS drugs are lower.
The National Institute of Allergy and Infectious Diseases (NIAID) were the sponsors of the trial dubbed HALT-MS. Immune Tolerance Network, which is funded by NIAID, conducted the research. The final reports were made available online in February 2015. They were published on Neurology, which is a medical journal run by the American Academy of Neurology. From the findings, one-time HDIT/HCT treatment is was considered more effective compared to the long-term treatment using available medication for MS patients.
About Shiva Gopal Vasishta
Dr. Shiva Gopal Vasishta is a New Jersey based psychiatry and neurology professional. In 1979, Vasishta graduated from medical school. He finished his residency at the Boston City Hospital. Dr. Shiva Gopal Vasishta has practiced for more than 38 years. He has extensive experience in the field of neurology and psychiatry.
Dr. Shiva Gopal Vasishta is licensed to practice in New Jersey. Additionally, Shiva is affiliated with the Eastern Neurodiagnostic Associates where he practices psychiatry. He maintains a close relationship with the management of Kennedy Health System Cherry Hill Campus. Dr. Shiva Gopal Vasishta accepts various insurance health plans. They include Medicare, Aetna, and Horizon Blue Cross Blue Shield.